NasdaqGS - Delayed Quote USD

Xeris Biopharma Holdings, Inc. (XERS)

Compare
3.2200 -0.0100 (-0.31%)
At close: October 31 at 4:00 PM EDT
3.1806 -0.04 (-1.22%)
Pre-Market: 9:25 AM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
181,413.0000
163,914.0000
110,248.0000
49,590.0000
20,435.0000
Cost of Revenue
29,532.0000
28,645.0000
22,634.0000
13,318.0000
9,328.0000
Gross Profit
151,881.0000
135,269.0000
87,614.0000
36,272.0000
11,107.0000
Operating Expense
189,067.0000
179,279.0000
169,554.0000
151,428.0000
94,653.0000
Operating Income
-37,186.0000
-44,010.0000
-81,940.0000
-115,156.0000
-83,546.0000
Net Non Operating Interest Income Expense
-23,419.0000
-21,858.0000
-11,524.0000
-6,867.0000
-7,695.0000
Other Income Expense
1,523.0000
2,364.0000
-2,620.0000
-702.0000
-9.0000
Pretax Income
-59,082.0000
-63,504.0000
-96,084.0000
-122,725.0000
-91,250.0000
Tax Provision
482.0000
-1,249.0000
-1,424.0000
--
-110.0000
Net Income Common Stockholders
-59,564.0000
-62,255.0000
-94,660.0000
-122,725.0000
-91,140.0000
Diluted NI Available to Com Stockholders
-59,564.0000
-62,255.0000
-94,660.0000
-122,725.0000
-91,140.0000
Basic EPS
-0.42
-0.45
-0.70
-1.55
-2.14
Diluted EPS
-0.42
-0.45
-0.70
-1.55
-2.14
Basic Average Shares
141,235.8800
137,674.8570
135,628.7210
79,027.0620
42,642.9010
Diluted Average Shares
141,235.8800
137,674.8570
135,628.7210
79,027.0620
42,642.9010
Total Operating Income as Reported
-37,186.0000
-44,010.0000
-81,940.0000
-115,156.0000
-83,546.0000
Total Expenses
218,599.0000
207,924.0000
192,188.0000
164,746.0000
103,981.0000
Net Income from Continuing & Discontinued Operation
-59,564.0000
-62,255.0000
-94,660.0000
-122,725.0000
-91,140.0000
Normalized Income
-60,767.1700
-64,572.5047
-92,078.8294
-122,023.0000
-91,131.0108
Interest Income
5,442.0000
4,751.0000
2,578.0000
313.0000
2,965.0000
Interest Expense
28,861.0000
26,609.0000
14,102.0000
7,180.0000
10,660.0000
Net Interest Income
-23,419.0000
-21,858.0000
-11,524.0000
-6,867.0000
-7,695.0000
EBIT
-30,221.0000
-36,895.0000
-81,982.0000
-115,545.0000
-80,590.0000
EBITDA
-17,237.0000
-23,735.0000
-69,314.0000
-113,666.0000
-79,123.0000
Reconciled Cost of Revenue
27,391.0000
26,328.0000
20,809.0000
11,989.0000
7,861.0000
Reconciled Depreciation
12,984.0000
13,160.0000
12,668.0000
1,879.0000
1,467.0000
Net Income from Continuing Operation Net Minority Interest
-59,564.0000
-62,255.0000
-94,660.0000
-122,725.0000
-91,140.0000
Total Unusual Items Excluding Goodwill
1,523.0000
2,364.0000
-2,620.0000
-702.0000
-9.0000
Total Unusual Items
1,523.0000
2,364.0000
-2,620.0000
-702.0000
-9.0000
Normalized EBITDA
-18,760.0000
-26,099.0000
-66,694.0000
-112,964.0000
-79,114.0000
Tax Rate for Calcs
0.0002
0.0000
0.0000
--
0.0000
Tax Effect of Unusual Items
319.8300
46.4953
-38.8294
--
-0.0108
12/31/2020 - 6/21/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers